Skip to search formSkip to main contentSkip to account menu

GM.CD40L cell vaccine

Known as: GM.CD40L 
A cell-based vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I/II randomized trial of GM.CD40L vaccine plus/minus CCL21 in advanced lung adenocarcinoma: Final results.
9037Background: Our GM.CD40L vaccine (an allogeneic tumor cell-based vaccine generated from human bystander cell line) recruits… 
2013
2013
A phase I/II randomized trial using GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine in combination with CCL21 in stage IV lung adenocarcinoma: Preliminary results.
3091 Background: Our GM.CD40L vaccine (an allogeneic tumor cell-based vaccine generated from human bystander cell line) recruits… 
2010
2010
Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results.
2608 Background: A phase I study showed that vaccination of cancer patients with irradiated autologous tumor cells and GM.CD40L… 
2008
2008
Ongoing Studies with GM.CD40L Bystander-Based Vaccines
2008
2008
Ongoing Studies with GM.CD40L Bystander-Based Vaccines
Drs Kobayashi and colleagues are correct in pointing out that patient selection, sample size, heterogeneity of patient… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)